Overall, the evidence for CDK4/6i continuation beyond progression is encouraging but mixed, underscoring the need for mechanistic studies of CDK4/6i-resistant proliferation to guide post-progression treatment strategies for HR+/HER2– breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.